We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
Read MoreHide Full Article
Agenus Inc. (AGEN - Free Report) is expected to report third-quarter 2017 on Oct 26. In the last reported quarter, the company delivered a positive earnings surprise of 11.11%, with a trailing four-quarter average of 4.27%.
Notably, Agenus’ shares have underperformed the industry year to date. The stock has been down 9.5%, as against the industry’s gain of 8.1%.
Let’s see how things are shaping up for the company this quarter.
Earnings Whispers
Our proven model shows that Agenus is likely to beat earnings in this quarter as it has the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — which have a significantly higher chance of beating earnings.
Zacks ESP: Agenus has an Earnings ESP of +8.11%. This is because the Most Accurate estimate of a loss of 34 cents comes in lower than the Zacks Consensus Estimate of a loss of 37 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Agenus’ Zacks Rank #2 when combined with a positive ESP makes us reasonably confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement.
Factors at Play
Agenus is an immuno-oncology company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer. It earns revenues only through fees received under collaboration and license agreements.
Currently, the company is evaluating AGEN1884 in a phase I study and INCAGN01876 in a phase I/II study, for the treatment of solid tumors. In fact, Agenus has initiated phase I study for anti-OX40 agonist antibody – INCAGN1949 – in a phase I/II study in collaboration with Incyte. It expects to begin combination studies on AGEN2034 and AGEN1884 in the second half of 2017.
In its third-quarter conference call, investors are likely to remain focused on the company’s update on the initiation of combination studies on these antibodies. They are expected to focus on the advancement of additional checkpoint modulator antibodies and vaccines into the clinic in the coming quarters.
In January 2017, Agenus entered into a clinical trial collaboration with the National Cancer Institute (NCI) to evaluate Prophage (HSPPC-96) in conjunction with Merck & Co., Inc.’s (MRK - Free Report) PD-1 therapy, Keytruda. A phase II study will evaluate the effect of Prophage, in conjunction with Keytruda, on the overall survival rate of patients with newly diagnosed glioblastoma (ndGBM).
Agenus recently announced that the FDA granted marketing authorization to GlaxoSmithKline's herpes zoster vaccine, Shingrix, containing Agenus' proprietary immune adjuvant QS-21 Stimulon. Shingrix is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. This is a positive for Agenus and can impact its business.
Here are some health care stocks that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +0.57% and a Zacks Rank #3. The company is scheduled to release results on Oct 26.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
Agenus Inc. (AGEN - Free Report) is expected to report third-quarter 2017 on Oct 26.
In the last reported quarter, the company delivered a positive earnings surprise of 11.11%, with a trailing four-quarter average of 4.27%.
Notably, Agenus’ shares have underperformed the industry year to date. The stock has been down 9.5%, as against the industry’s gain of 8.1%.
Let’s see how things are shaping up for the company this quarter.
Earnings Whispers
Our proven model shows that Agenus is likely to beat earnings in this quarter as it has the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — which have a significantly higher chance of beating earnings.
Zacks ESP: Agenus has an Earnings ESP of +8.11%. This is because the Most Accurate estimate of a loss of 34 cents comes in lower than the Zacks Consensus Estimate of a loss of 37 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Agenus’ Zacks Rank #2 when combined with a positive ESP makes us reasonably confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement.
Factors at Play
Agenus is an immuno-oncology company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer. It earns revenues only through fees received under collaboration and license agreements.
Currently, the company is evaluating AGEN1884 in a phase I study and INCAGN01876 in a phase I/II study, for the treatment of solid tumors. In fact, Agenus has initiated phase I study for anti-OX40 agonist antibody – INCAGN1949 – in a phase I/II study in collaboration with Incyte. It expects to begin combination studies on AGEN2034 and AGEN1884 in the second half of 2017.
In its third-quarter conference call, investors are likely to remain focused on the company’s update on the initiation of combination studies on these antibodies. They are expected to focus on the advancement of additional checkpoint modulator antibodies and vaccines into the clinic in the coming quarters.
In January 2017, Agenus entered into a clinical trial collaboration with the National Cancer Institute (NCI) to evaluate Prophage (HSPPC-96) in conjunction with Merck & Co., Inc.’s (MRK - Free Report) PD-1 therapy, Keytruda. A phase II study will evaluate the effect of Prophage, in conjunction with Keytruda, on the overall survival rate of patients with newly diagnosed glioblastoma (ndGBM).
Agenus recently announced that the FDA granted marketing authorization to GlaxoSmithKline's herpes zoster vaccine, Shingrix, containing Agenus' proprietary immune adjuvant QS-21 Stimulon. Shingrix is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. This is a positive for Agenus and can impact its business.
Agenus Inc. Price and EPS Surprise
Agenus Inc. Price and EPS Surprise | Agenus Inc. Quote
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Seattle Genetics, Inc. has an Earnings ESP of +5.74% and a Zacks Rank #3. The company is scheduled to release results on Oct 26. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +0.57% and a Zacks Rank #3. The company is scheduled to release results on Oct 26.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>